Molecular Neurobiology

, Volume 36, Issue 1, pp 75–81

The Endocannabinoid System and Alzheimer’s Disease

  • Cristina Benito
  • Estefanía Núñez
  • María Ruth Pazos
  • Rosa María Tolón
  • Julián Romero
Article

DOI: 10.1007/s12035-007-8006-8

Cite this article as:
Benito, C., Núñez, E., Pazos, M.R. et al. Mol Neurobiol (2007) 36: 75. doi:10.1007/s12035-007-8006-8

Abstract

The importance of the role of the endocannabinoid system (ECS) in neurodegenerative diseases has grown during the past few years. Mostly because of the high density and wide distribution of cannabinoid receptors of the CB1 type in the central nervous system (CNS), much research focused on the function(s) that these receptors might play in pathophysiological conditions. Our current understanding, however, points to much diverse roles for this system. In particular, other elements of the ECS, such as the fatty acid amide hydrolase (FAAH) or the CB2 cannabinoid receptor are now considered as promising pharmacological targets for some diseases and new cannabinoids have been incorporated as therapeutic tools. Although still preliminary, recent reports suggest that the modulation of the ECS may constitute a novel approach for the treatment of Alzheimer’s disease (AD). Data obtained in vitro, as well as in animal models for this disease and in human samples seem to corroborate the notion that the activation of the ECS, through the use of agonists or by enhancing the endogenous cannabinoid tone, may induce beneficial effects on the evolution of this disease.

Keywords

Endocannabinoid system Alzheimer’s disease Animal models 

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Cristina Benito
    • 1
  • Estefanía Núñez
    • 1
  • María Ruth Pazos
    • 1
  • Rosa María Tolón
    • 1
  • Julián Romero
    • 1
  1. 1.Laboratorio de Apoyo a la InvestigaciónFundación Hospital AlcorcónAlcorcónSpain

Personalised recommendations